Evogene Ltd.
EVGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $10,654 | $38,376 | $28,847 | $672,622 |
| - Cash | $15,301 | $20,772 | $28,980 | $32,325 |
| + Debt | $12,874 | $11,506 | $11,930 | $2,669 |
| Enterprise Value | $8,227 | $29,110 | $11,797 | $642,966 |
| Revenue | $8,511 | $5,640 | $1,675 | $930 |
| % Growth | 50.9% | 236.7% | 80.1% | – |
| Gross Profit | $3,388 | $1,399 | -$1,774 | -$2,071 |
| % Margin | 39.8% | 24.8% | -105.9% | -222.7% |
| EBITDA | -$15,378 | -$23,204 | -$26,933 | -$27,795 |
| % Margin | -180.7% | -411.4% | -1,607.9% | -2,988.7% |
| Net Income | -$16,485 | -$23,879 | -$26,638 | -$27,793 |
| % Margin | -193.7% | -423.4% | -1,590.3% | -2,988.5% |
| EPS Diluted | -2.89 | -5.23 | -6.46 | -0.68 |
| % Growth | 44.7% | 19% | -850% | – |
| Operating Cash Flow | -$19,700 | -$21,577 | -$23,678 | -$24,839 |
| Capital Expenditures | -$626 | -$785 | -$1,171 | -$724 |
| Free Cash Flow | -$20,326 | -$22,362 | -$24,849 | -$25,563 |